A combined regimen of etretinate and UVB modulate T6+ and HLA-DR+ epidermal cells
Journal of Korean Medical Science
;
: 89-96, 1987.
Artigo
em Inglês
| WPRIM
| ID: wpr-214024
ABSTRACT
Using anti-T6 and anti-HLA-DR monoclonal antibodies, this study was designed to attain what would do to epidermal Langerhans cell (LC) markers in psoriatic patients when two remedies, etretinate and UVB, having controversial effects on LC were put to use simultaneously. In normal and psoriatic subjects, HLA-DR+ LC was approximately 80% of T6+ LC and a single dose of UVB equivalent to minimal erythema dose (MED), reduced LC membrane markers to approximately 30% of non-irradiated control. The recovery of LC membrane markers, after a single dose of UVB exposure were significantly faster in the group of etretinate treated psoriatic subject than only UVB irradiated psoriatic control. Taken together, seemed to exert prompt recovery of normalization of the number of LC from the depletion following the UVB.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Psoríase
/
Terapia Ultravioleta
/
Imuno-Histoquímica
/
Etretinato
/
Antígenos de Diferenciação de Linfócitos T
/
Antígenos HLA-DR
/
Células de Langerhans
/
Quimioterapia Combinada
/
Anticorpos Monoclonais
Limite:
Adulto
/
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Journal of Korean Medical Science
Ano de publicação:
1987
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS